Nathaly Segovia, Scientific coordinator of NANBIOSIS U 6, Biomaterial Processing and naostructuring unit, explains in this video what the objective of her unit , the services they offer and their technologies in the field of drug delivery.
Miriam Royo, Scientific Coordinator of Unit 3 of NANBIOSIS explains in this video the expertise of the unit in the preparation of difficult peptides (Cyclid and polycyclic peptides, stapled peptides and dificult peptides, depsipetides, natural products and libraries, peptidomimetic libraries, peptides as antigens or adjuvants, tarjeted drug conjugates, etc… as well as therapeutic agen-PEG-targeting unit conjugates
Victor Sebastian, researcher of NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit, explains the production technologies in continuous (Microfluidic systems liquid phase or pyrolysis activated by laser, gas phase in which the nanoparticles are produced)
Jordi Esquena, Coordinador científico de la Unidad 12 de NANBIOSIS Nanostructured liquid characterization unit taks about the Autoagregation to surfactant systems
En este vídeo Jose Francisco Guillen Caro, Responsable de garantía de calidad del CCMIJU presents the Jesús Usón Minimum Invasion Surgery Center in Cáceres and, especially, the UMISC units that integrate NANBIOSIS, as well as the services and tests they perform, which are certified as GLP
Scientists of NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit are coauthors of of the New cover ACS Sustainable Chem. Eng.
Sustainable Production of Drug-Loaded Particles by Membrane Emulsification. Albisa A, Piacentini E, Arruebo M, Sebastian V, Giorno L. ACS Sustainable Chem. Eng., 2018, 6 (5), pp 6663–6674 March 13, 2018. DOI: 10.1021/acssuschemeng.8b00401. IF: 5,951
Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN.
Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS units) got together to explain, through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations in the area of Nanomedicine apllications in drug delivery and targeting. There was also a talk by a representative of CDTI (Spanish National Center for Industrial and Technological Development) to explain the financing opportunities for the companies as well as a presentation by the NANBIOSIS Coordinator, Jesús Izco, to show the new Cutting Edge Biomedical Solutions offered by the ICTS-NANBIOSIS.
After lunch, the groups and companies had the opportunity to discuss in more detail, during bilateral interviews coordinated by NANBIOSIS a, those aspects that had attracted their attention, as well as, in some cases, to draw potential collaborations. The event was successfully developed with 45 attendees and more than 50 individual B2B mettings.
Jaume Veciana, Scientific Director of NANBIOSIS is co-author of the publication “Robust Organic Radical Molecular Junctions Using Acetylene Terminated Groups for C–Au Bond Formation” by “Journal of the American Chemical Society”.
For further information:
MATERPLAT, the Technological Platform of Advanced Materials and Nanomaterials, has presented the “Spanish technological strategy of advanced materials and nanomaterials” in whose preparation NANBIOSIS has participated. This document seeks to collect and reflect the technological challenges, needs and barriers associated with industrial sectors that clearly require innovation in advanced materials, as well as in their processes and / or products, to ensure their competitiveness, sustainability and growth.
For further information:
Pablo Laguna, Scientific Director of NANBIOSIS Unit 27, has recently been appointed as a select member (IEEE fellow) of the Institute of Electrical and Electronics Engineers within the society of Medical Engineering and Biology -IEEE-EMBS-.
The grade of Fellow recognizes unusual distinction in the profession and is conferred only by invitation of the IEEE Board of Directors upon a person with an extraordinary record of accomplishments in any of IEEE’s designated fields of interest, in this case, Dr. Laguna is recognized for his contributions to cardiac biomedical signal processing.
The IEEE-EMBSis the world’s largest international society of biomedical engineers. The 11,000 members of the organization reside in some 97 countries around the world. EMBS provides its members access to people, information, ideas and opinions that are shaping one of the fastest growing fields in science.
Pablo Laguna is Professor of Signal Theory and Communications at the School of Engineering and Architecture (EINA) and group leader of the CIBER-BBN and University of Zaragoza research group BSICoS . His work focuses on the search of non-invasive indexes to predict the risk of arrhythmias, the modeling and simulation of cardiac electrophysiology, the evaluation and quantification of the activity of the autonomic nervous system and the processing and characterization of biomedical signals in respiratory pathologies. He has been Scientific Director of the CIBER-BBN from 2011 to 2015.
